Your buyers' coverage will soon depend on how your product performs.
Idem certifies clinical AI products against the same published standard used to assess, and insure, the hospitals that deploy them.
Self-attestation is losing its weight.
Most health systems still let the vendor decide how its AI should be used: among those with partial governance, 70% do. That is changing. The Joint Commission and CHAI expect hospitals to validate locally, carriers are adding AI questions at renewal, and the largest US malpractice insurer has said AI liability should sit with developers.
Your own coverage is moving too. W.R. Berkley filed an absolute AI exclusion on E&O, and ISO exclusions took effect in general liability in January 2026.
Independent evidence your buyers can take to their insurer.
Your product validated on representative clinical data against the same criteria used in hospital assessments.
Written for a buyer's AI governance committee and readable by their insurer's underwriter.
The certification tracks the version your customers run.
A clear view of what a hospital's local validation will test, so fewer surprises after go-live.
Your company pays for its certification. You never pay for, see in advance, or influence the result of a hospital's validation, and certification does not guarantee a passing tier at any customer site. Idem sells no AI products and takes no implementation work.
CEOs, chief medical officers, and heads of regulatory, quality, and clinical affairs at companies selling scribes, summarization, clinical decision support, and diagnostic AI into US health systems.
Read the evidence.
Then let's talk.
The June 2026 white paper documents what EHR-native AI features are doing in the medical record and what your organization is on the hook for.